Patient waited more than 330 hours in emergency department
Conditions in emergency departments (EDs) are "soul destroying", a senior consultant has said after it was revealed that one patient waited more than 330 hours inside a unit.
New figures, obtained by BBC News NI, show that in a seven-month period to January this year, one patient waited two weeks at the Ulster Hospital, while another waited 11 days at the Mater in Belfast.
Dr Clodagh Corrigan, deputy chair of the British Medical Association in Northern Ireland, said conditions in EDs for staff and patients were "horrific".
In a statement, the Department of Health (DoH) acknowledged that waiting times in EDs "fall well below the standard of care that we strive to provide".
The DoH target is for 95% of patients to be treated, discharged or admitted within four hours and no patient to wait longer than 12 hours.
Dr Corrigan, who is an emergency medicine consultant, has called on the department to spend its money more effectively.
A Freedom of Information request from BBC News NI revealed that every health trust in Northern Ireland experienced patient waits of about week or more.
The Northern Health Trust said a wait of more than 10 days for a patient in Antrim Area Hospital was because they needed to be isolated in a side room for other people's safety.
"If there's space, it's taken up by somebody," said Dr Corrigan.
She added that patients who might be vomiting or suffering from diarrhoea were queuing for the one toilet available in a unit.
"It's a soul-destroying work environment. You can't give the care you want to give," she said.
"You certainly aren't giving the care you're trained to give. It's not the care you'd want your family to receive."
There are currently hundreds of people stuck in hospitals across Northern Ireland who are medically fit to be discharged but do not have a care package or an appropriate facility to go to.
The BMA said this increases pressure in EDs because people are not moving through the hospital system.
The BBC requested data from all five health trusts under Freedom of Information, including that relating to the height of the winter pressures over Christmas and New Year.
They reflect the immense pressure healthcare staff were under at the time, with one nursing leader describing conditions as "intolerable".
Between 12 December 2024 and 20 January this year, 140 patients had to wait in crowded EDs for more than 100 hours.
At Altnagelvin Area Hospital, one person spent a week in its ED.
The hospital recorded the highest number of patients waiting the longest times, with 48 people waiting for more than 100 hours.
Dr Corrigan said the BMA was calling for greater investment in the health service and multi-year budgets.
"The money that exists needs to be used better. There's been an awful lot of investment in a lot of new initiatives... and while we welcome some of those initiatives, we're not seeing the pressures easing from them," she said.
"It might be better investing in the services that are already here and shaping them better."
In a statement, the Department of Health said Health Minister Mike Nesbitt was "acutely aware of the pressures within emergency departments".
"The department also recognises the risk of possible harm to patients who experience long waiting times in ED and is working with trusts to improve patient flow through urgent and emergency care," it added.
There were still major waits for patients in EDs this week, with patients at Craigavon Area Hospital waiting an average of 15 hours to be seen on Monday.
Patients 'frightened' to go to hospital over lengthy ED waits
Elderly patients' five-day wait in 'intolerable' A&E
Ambulance patient waits 19 hours outside hospital
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
36 minutes ago
- Yahoo
Sana Biotechnology (SANA) Stock Surges on Positive Type 1 Diabetes Treatment Results
Sana Biotechnology, Inc. (NASDAQ:SANA) is one of the 10 best healthcare penny stocks to buy according to analysts. The company's stock surged 12.1% on June 23 after it announced positive six-month follow-up results from an investigator-sponsored, first-in-human study of its type 1 diabetes treatment. A laboratory cultivating cells for the development of gene and cell therapies. The therapy in focus is UP421, which consists of cadaver-sourced pancreatic islet cells that have been genetically modified using Sana's hypoimmune (HIP) technology to evade immune detection. A significant finding is that the transplanted cells were safe, well-tolerated, survived, and continued to produce insulin in the patient without the need for immunosuppressive medicines. The study identified no safety issues, and the HIP-modified islet cells successfully evaded immune responses (both allogeneic and autoimmune). Per-Ola Carlsson, MD, Study Principal Investigator, Senior Physician, and Professor at the Clinic for Uppsala University Hospital, stated that the consistent results at four-week, 12-week, and now six-month follow-ups continue to suggest that a functional cure for type 1 diabetes without immunosuppression is possible. Sana Biotechnology, Inc. (NASDAQ:SANA) is a biotechnology company. It develops engineered cell therapies to treat serious diseases, aiming to repair or replace damaged cells. Its platforms include hypoimmune cells, gene delivery, and in vivo cell engineering. Sana's pipeline targets conditions like cancer, type 1 diabetes, and genetic disorders. While we acknowledge the potential of SANA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Goldman Sachs Energy Stocks: 10 Stocks to Buy and 10 Best AI Stocks to Buy According to Billionaire David Tepper. Disclosure: None.
Yahoo
an hour ago
- Yahoo
This Dirt Cheap Healthcare Stock Could Be a Hidden Artificial Intelligence (AI) Opportunity (Hint: It's Not Eli Lilly)
One major potential use case for AI in healthcare is drug discovery for pharmaceutical companies. Insurance is another healthcare-related industry likely to benefit from AI, which could aid scenario modeling, predictive analytics, and natural language processing. UnitedHealth Group experienced some operational challenges this year, but AI could wipe away these shortcomings in the long run. 10 stocks we like better than UnitedHealth Group › When it comes to popular healthcare stocks, investors have focused a lot of attention lately on Eli Lilly and Novo Nordisk and the potential of their blockbuster weight management treatments, including Mounjaro, Zepbound, Ozempic, and Wegovy. While these drugs are likely to lead to billions in revenue, Lilly and Novo aren't relying solely on these drugs to grow their businesses. Both companies are also looking into the potential that artificial intelligence (AI) can bring to their operations -- and for good reason. Accounting and consulting firm PwC estimates that the total addressable market (TAM) for AI in healthcare could reach $868 billion by 2030. One of the obvious applications that AI has for healthcare is facilitating pharmaceutical companies in clinical trials and drug discovery. While such use cases are exciting, I see another pocket of the healthcare industry that could be positively disrupted by AI: insurance. Let's explore why UnitedHealth Group (NYSE: UNH) could be an under-the-radar growth opportunity because of the intersection between healthcare and AI. Back in April, UnitedHealth greatly disappointed investors after the company published revised financial guidance that indicated a lower-than-expected earnings outlook for the remainder of the year. Management blamed the lower profitability on two primary factors. First, utilization rates in the company's Medicare Advantage program exceeded internal forecasts, taking a toll on the company's cost structure. Second, reimbursements in the company's pharmacy benefits management (PBM) platform, Optum Health, were negatively impacted by reductions in Medicare funding as well as changes to some of the patient demographic profiles in this segment of the business. In short order, the stock price plunged and has shown no indications of recovery, so far. For 2025, share prices are down 40%, making UnitedHealth the poorest-performing stock in the Dow Jones Industrial Average this year. But before you go writing UnitedHealth off as a broken business, let's examine how AI has the potential to help the health insurance industry and how UnitedHealth specifically could implement this technology to improve the business over time. The underlying issue surrounding UnitedHealth's challenges right now has to do with forecasting. There isn't anything fundamentally broken with the business. Rather, unforeseen changes in the macroeconomic environment led to a different reality than what management had previously modeled -- ultimately leading to higher costs and compressed profit margins. By using machine learning, UnitedHealth could train AI models on claims data and subsequently integrate these feeds into electronic health records (EHR) to help predict more accurate utilization trends. More efficient data feeds could help UnitedHealth hone its pricing strategy and better plan for cost spikes. In addition, AI has the ability to build predictive models that can more accurately assess patient risk profiles. In theory, this has the potential to analyze more granular detail around various segments of patient data as it relates to engagement rates and risk profiles. This could help improve reimbursement forecasts for the Optum business. Lastly, natural language processing (NLP) can also be used to create scenario models by simulating how a business could be impacted based on changes in the regulatory landscape. An example of a company that specializes in this area of AI training is FiscalNote. This could help UnitedHealth plan more strategically as it pertains to budgeting decisions during periods of political uncertainty. While shares of UnitedHealth trade at a slight premium to other large health insurers based on forward earnings multiples, the bigger takeaway from the trends below is that the stock price is hovering near a five-year low. While UnitedHealth's operational challenges won't be fixed overnight, it is key to remember that management believes the company can course correct throughout the second half of this year and be better positioned by 2026. Whether UnitedHealth transitions into an AI-powered service remains to be seen. Investors with a long-run time horizon might want to consider holding on to their shares, though, as the ideas explored above showcase how AI has the potential to become a game-changing advancement for the health insurance industry over time. Looked at a different way, UnitedHealth could transform its business over the next several years by making cognizant investments in this technology. Nevertheless, the stock appears dirt cheap right now, and I think patient investors will be rewarded as the company turns things around over the next couple of quarters. Before you buy stock in UnitedHealth Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and UnitedHealth Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!* Now, it's worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 177% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 Fiscal Note is a transcription service used by The Motley Fool. Adam Spatacco has positions in Eli Lilly and Novo Nordisk. The Motley Fool recommends Novo Nordisk and UnitedHealth Group. The Motley Fool has a disclosure policy. This Dirt Cheap Healthcare Stock Could Be a Hidden Artificial Intelligence (AI) Opportunity (Hint: It's Not Eli Lilly) was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Washington Post
2 hours ago
- Washington Post
I got an ambulance ride, CT scan and ER care in Brazil. My bill: $0.
PARATY, Brazil — My son had a high fever, so my wife and I decided to cut short our beach vacation and head home, worried about the quality of health care so far from Rio de Janeiro. I packed our bags, took one last look at the calm shoreline and headed out to load up the car.